Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 151,241

Document Document Title
WO/2018/132787A1
Recombinant IL-11 is expressed in yeast, then isolated from aerobic fermentation media by precipitation, solubilization of the precipitate in the presence of a denaturant, and renaturation of the solubilized protein. Renatured rhIL-11 is...  
WO/2018/132695A1
The invention provides chimeric antigen receptors (CARs) that specifically bind to the T-cell immunoglobulin and mucin domain 1 (TIM-1) protein. The invention further relates to modified immune cells, e.g., T or NK cells, comprising such...  
WO/2018/132572A1
R-spondin (RSPO) surrogate compositions and methods for their use are provided. RSPO surrogates of the invention comprise (i) a specific binding domain for Ring Finger Protein 43 (RNF43) or Zinc and Ring Finger Protein 3 (ZNRF3) and (ii)...  
WO/2018/132513A1
Described herein are methods for producing and utilizing T cells comprising chimeric antigen receptors (CAR) comprising a portion of the extracellular domain of a Tumor Necrosis Factor (TNF) superfamily receptor ligand, e.g., A PRolifera...  
WO/2018/132747A1
Vectors having a nucleotide sequence having SEQ ID NO:1 or a nucleotide sequence having at least 85% identity to SEQ ID NO:1, or a portion thereof, that is capable of regulating bocaparvovirus replication, or vectors having the complemen...  
WO/2018/132506A1
Described herein are methods for producing and utilizing an alternative signal 1 domain to construct an optimally signaling CAR. Alternative signal 1 domains of the present technology are based on alternatives to CD3ζ, including mutated...  
WO/2018/130790A1
The invention relates to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO : 1, said peptide having an amino acid sequence selected from the group consisting of: a) the seq...  
WO/2018/130659A1
The invention relates to apolypeptide capable of binding to TGF-β for use in treating or preventing a condition associated with elevated or unwanted levels of TGF-β, wherein said polypeptide is capable of inhibiting theinteraction of T...  
WO/2018/132658A1
Disclosed herein are viruses and compounds for use in the treatment of cancer.  
WO/2018/132739A2
Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subj...  
WO/2018/129618A1
The present disclosure relates to compounds of Formula (I) which are multimeric forms of a monomeric binding peptide linearly bonded to PEG moieties to form the multimers. The multimeric forms stimulate angiogenesis and promote wound hea...  
WO/2018/130871A1
A system, method, apparatus and diagnostic test for Plasmodium vivax, to determine a likelihood of a specific timing of infection by P. vivax in a subject, and hence identify individuals with a high probability of being infected with oth...  
WO/2018/130835A1
The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide mole...  
WO/2018/130834A1
The present invention relates to novel peptides derivable from the polypeptide chaperonin 60.1 and to their use in medicine, such as for the prevention and/or treatment of inflammatory conditions.  
WO/2018/130060A1
An application of BS1-CT protein in regulating deacetylation of xylan in a plant cell wall. The BS1-CT protein is the following protein a) or b) or c): a) a protein having an amino acid sequence as shown at positions 25-382 of SEQ ID NO:...  
WO/2018/132423A1
The present disclosure relates to chimeric neurotoxins and uses thereof. In particular, provided herein are chimeric botulinum neurotoxins with altered properties and uses thereof (e.g., research, screening, and therapeutic uses).  
WO/2018/130836A1
A method of diagnosing or monitoring Mycobacterium avium subspecies paratuberculosis (MAP) infection, which method comprises detecting the presence of the polypeptide (MAP P900) encoded by the positive strand of IS900, or a fragment ther...  
WO/2018/129624A1
The present invention provides a vaccine comprising a peptide antigen, one terminal end being coupled to a carrier molecule, and the other terminal end of the peptide being linked to a non-immunogenic moiety such as a saccharide. The thu...  
WO/2018/130554A1
The present invention relates to a method for obtaining extracellular vesicles derived from mesenchymal stromal cells (MSCs), wherein the extracellular-vesicles are essentially free of vesicles not derived from the MSCs, and wherein the ...  
WO/2018/129767A1
Provided is a recombinant virus, the recombinant virus being obtained by mutating a codon, which encodes a tyrosine residue at position 385 of an NP protein in a genome of type A influenza virus, into a codon of a phenylalanine residue. ...  
WO/2018/132409A1
A method for treating cystic fibrosis, including administering to a subject an effective amount of a microvesicle containing a cystic fibrosis transmembrane conductance regulator (CFTR) protein. A method for replacing a defective CFTR pr...  
WO/2018/132842A1
Engineered photoconvertible fluorescent proteins (pcFPs) that have been rendered primed convertible include green-to-red pcFP that has been mutated to introduce a threonine at the fifth amino acid position following a chromophore in the ...  
WO/2018/132774A1
Methods and systems are provided for generating and utilizing a bacterial composition that comprises at least one genetically engineered bacterial strain that fixes atmospheric nitrogen in an agricultural system that has been fertilized ...  
WO/2018/132768A1
Disclosed are engineered corticotropin-releasing factor (CRF) antagonist agents, including engineered corticotropin-releasing factor (CRF) binding agents. The CRF antagonist agents and binding agents can be used to neutralize excess CRF ...  
WO/2018/132457A1
In various embodiments, an information storage system comprises: a writing device for synthesizing a nucleotide sequence that encodes a set of information; and a reading device for interpreting the nucleotide sequence by decoding the int...  
WO/2018/130839A1
The present invention relates, to a laminin receptor peptide for use in the treatment of amyotrophic lateral sclerosis (ALS), which is also known as Motor Neurone Disease (MND) and can include Frontotemporal Dementia (FTD). The invention...  
WO/2018/130170A1
A high-affinity peptide for a tumor necrosis factor alpha. Amino acid sequences of the peptide are as represented by SEQ.ID.NO.1 and SEQ.ID.NO.3 or are tandem or branched peptide molecular sequences with a single repeat or multiple repea...  
WO/2018/126317A1
Compositions and methods for treating cancer in humans are provided using CARs. The invention includes engineered CARs (chimeric receptor antigens) and genetically modified immune cells that express such a CAR with a high affinity for VE...  
WO/2018/127733A1
Provided are peptide nucleic acid derivatives targeting a 3' splice site of the human SNAP25 pre-mRNA. The peptide nucleic acid derivatives potently induce at least a splice variant of the human SNAP25 mRNA in cells, and are useful to sa...  
WO/2018/129231A1
The present invention is directed to a method for treating multiple sclerosis by administering dapansutrile to a subject in need thereof. A preferred route of administration is oral administration.  
WO/2018/129474A1
The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions ...  
WO/2018/127494A1
The present invention relates to novel bicyclic antimicrobial lanthipeptides, their corresponding peptide leader sequences, and the production thereof.  
WO/2018/128486A1
The present invention relates to an anti-CEACAM6 chimeric antigen receptor (CAR) specifically binding to CEACAM6, and a cell therapeutic agent comprising same. The chimeric antigen receptor according to the present invention is character...  
WO/2018/129524A1
Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antig...  
WO/2018/128931A1
Provided is a pharmaceutical composition, including an antigen fusion protein which includes an antigen and an antagonist of an Fc gamma receptor. Also provided is a method of enhancing immunogenicity of an antigen, including conjugating...  
WO/2018/129199A1
The invention provides modified Natural Killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex. These NK cells are used for T cell receptor (TCR) gene therapy in order to circumvent any risk of mispairi...  
WO/2018/129346A1
Provided are CD96-modified and TIGIT-modified NK-92 cells comprising one or more alterations that inhibit expression of CD96 and/or TIGIT. Also provided are methods of generating such modified NK-92 cells and methods of treating a subjec...  
WO/2018/127917A1
PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 ami...  
WO/2018/129306A1
Provided herein are recombinant fusion polypeptides comprising an HPV16 antigenic peptide and an HPV18 antigenic peptide, wherein the HPV16 antigenic peptide and the HPV18 antigenic peptide are operably linked in tandem (e.g., fused to a...  
WO/2018/128587A1
Disclosed is an isolated variant of SMCHD1 peptide, or fragment thereof, comprising one or more mutation(s) that increases SMCHD1 activity in a cell compared to a cell with a wild- etype SMCHD1 peptide. Also disclosed are isolated nuclei...  
WO/2018/128828A1
The present invention relates to novel peptides acting as hepcidin mimetics, as well as analogues and derivatives thereof. The invention further relates to compositions comprising the peptides of the present invention, and to the use of ...  
WO/2018/129544A1
The invention relates to methods of modulating the expression of one or more genes in a cell by modulating the multimerization of a transcription factor and/or modulating the formation of enhancer-promoter DNA loops, and thereby modulati...  
WO/2018/129536A1
In alternative embodiments, provided are compositions, products of manufacture and methods for treating, ameliorating and preventing infections, disorders and conditions in animals including: delivering a (i) bacteriophage (ii) prophage,...  
WO/2018/128485A1
The present invention relates to a natural killer cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent comprising same. The natural killer cell expressing a chime...  
WO/2018/127830A1
The present invention relates to a composition which comprises peptides derived from S- Arrestin (retinal arrestin, S-antigen, S-Ag). The composition or peptides may be useful in the prevention and/or suppression of S-Ag autoimmunity, wh...  
WO/2018/129007A1
Methods of generating conditionally active proteins that target senescent cells and which are conditionally active in an extracellular environment of a senescent cell. The methods include discovery methods using libraries of evolved prot...  
WO/2018/127382A1
In certain aspects, the disclosure relates to compositions comprising modified Ornithine transcarbamylase (OTC) polyribonucleotides and methods of use.  
WO/2018/128140A1
The present invention identifies a gene cluster contributing to the biosynthesis of a cyclic peptide compound produced by Curvularia filamentous fungi, and establishes a system for synthesizing said cyclic peptide compound. The present i...  
WO/2018/127916A1
PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino a...  
WO/2018/127829A1
The present invention relates to a composition comprising a peptide derived from myelin basic protein (MBP) peptide for use in treating or preventing uveitis in a subject  

Matches 1 - 50 out of 151,241